Why insider trading matters?
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
- Peter Lynch
Why insider trading matters?
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. It primarily serves physicians and pharmacists through direct sales. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2017-10-30 | CHAWLA SAM | Director | Buy | 3,100,000 | $3.05 | $9,455,000 | No |
| 2017-10-26 | PERCEPTIVE ADVISORS LLC | 10%-Owner | Buy | 3,100,000 | $3.05 | $9,455,000 | No |
| 2017-08-21 | Diaz-Mitoma Francisco | Chief Medical Officer | Buy | 3,000 | $3.17 | $9,510 | No |
| 2017-08-21 | Baxter Jeff | CEO, President | Buy | 10,000 | $3.22 | $32,200 | No |
| 2017-08-10 | Baxter Jeff | CEO, President | Buy | 10,000 | $3.28 | $32,800 | No |
Insider Smart
Insider Smart